Related Experiment Video
Updated: Oct 4, 2025
Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma
Published on: November 4, 2010
Deprescribing montelukast in children with asthma: a systematic review
Eleanor Grace Dixon1,2, Charlotte King3, Andrew Lilley4
1Department of Pharmacology and Therapeutics, University of Liverpool Faculty of Health and Life Sciences, Liverpool, UK.
Insights
Deprescribing montelukast in children with asthma shows limited, contradictory short-term effects. Further research is needed to establish safe asthma treatment guidelines for this age group.
Area of Science:
- Pediatric Pulmonology
- Pharmacology
- Clinical Medicine
Background:
- Current asthma guidelines lack specific advice on discontinuing montelukast in children and young people (CYP).
- This study addresses the gap in evidence for safely stepping down montelukast treatment in pediatric asthma patients.
Purpose of the Study:
- To systematically review existing evidence on the deprescribing of montelukast in CYP with established asthma.
- To evaluate the impact and safety of withdrawing montelukast in this population.
Main Methods:
- A systematic review of studies was conducted, searching Embase, Medline, PubMed, and CINAHL up to October 2020.
- Included studies involved CYP (0-18 years) diagnosed with asthma who had previously used montelukast.
- Outcomes assessed included lung function tests (e.g., FEV1, FeNO), asthma scores, and exercise challenges.
Main Results:
- Five studies (3 RCTs, 2 cohort) were included, with follow-up periods of 2-8 weeks.
- No significant differences in lung function were observed between montelukast and placebo groups post-withdrawal.
- Some outcomes showed significant changes within the test group, including decreases in FEV1 and increases in FeNO, indicating mixed effects.
Conclusions:
- The available literature on deprescribing montelukast in CYP with asthma is limited, contradictory, and focuses on short-term effects.
- More definitive studies are crucial to assess clinical stability and the long-term impact of discontinuing montelukast.
- Improved evidence is imperative for enhancing the safety of asthma management in children and young people.
Background:
National and international asthma guidelines recommend adjusting asthma treatment based on levels of control, yet no guidance is given regarding the stepping-down of montelukast in children and young people (CYP).
Objective:
To systematically review evidence regarding deprescribing montelukast in CYP with established asthma.
Design:
Systematic review.
Data Sources:
Embase, Medline, PubMed and CINAHL were searched up to October 2020.
Study Selection:
Eligible studies contained patients aged 0-18 years with a diagnosis of asthma, who had been administering montelukast before it was withdrawn. All reasons for withdrawal were included.
Results:
The search identified 197 papers. After deduplication, five papers were included (three randomised control studies and two cohort studies). Four studies observed the impact of montelukast withdrawal for 2 weeks, and one study for 8 weeks. The impact of withdrawal was measured in the studies using a combination of lung tests (eg, forced expiratory volume in 1 s (FEV1), fractional exhaled nitric oxide (FeNO)), asthma scoring methods and exercise challenges. Of the 17 domains in the Core Outcome Set for Clinical Trials in Childhood Asthma, eight outcomes were measured in at least one of the five studies, with all five studies measuring the outcome of 'Lung Function'. No significant differences were found between the montelukast and placebo groups following montelukast withdrawal. Significant differences between the comparator points within the test group were found in nine outcomes across four studies; FEV1/forced vital capacity, FEV1, forced expiratory flows (25%-75%), asthma score (study specific), maximum % fall in FEV1 and time to recovery (post exercise) significantly decreased whereas FEV1/bronchodilator response, FeNO and eNO significantly increased.
Conclusion:
Only limited, contradictory and short-term effects of deprescribing montelukast in CYP with established asthma are presented in literature. Definitive studies determining clinical stability, and impact of deprescribing montelukast in CYP are imperative to improve the safety of asthma treatment in CYP.
Prospero Registration Number:
CRD42020213971.
Related Concept Videos
01:19Antiasthma Drugs: Leukotriene Modifiers
Leukotriene modifiers work through two distinct mechanisms:
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
01:30Asthma-IV: Diagnostic and Management
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
01:20Asthma: Pathogenesis and Management
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
01:30Asthma-IV: Nursing Management
First, in...
01:26Asthma-II: Pathophysiology and Classification
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include: